SCHEMBL18317396

SCHEMBL18317396

[c]1ccc(-c2ccc(C3C4CC5CC(C4)CC3C5)cc2)cc1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.33
CYP2C9 P11712 1/20 0.33
ESR2 Q92731 1/20 0.33
TEAD1 P28347 1/20 0.31
PAX8 Q06710 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1522062 0.88 ESR1 (0.33) ESR1CYP2C9ESR2TEAD1
SCHEMBL18317241 0.81 HTR2C (0.33)
SCHEMBL2763439 0.81 CYP2C9 (0.41) ESR1CYP2C9ESR2TEAD1
SCHEMBL27602398 0.80 KDM1A (0.48) PAX8
SCHEMBL18318002 0.74 PAX8 (0.30) PAX8
SCHEMBL25181452 0.71 KDM1A (0.45) ESR1CYP2C9ESR2
SCHEMBL3148759 0.71 ESR2 (0.56) ESR1CYP2C9ESR2TEAD1
SCHEMBL14299432 0.71 KDM1A (0.45) ESR1CYP2C9ESR2PAX8
SCHEMBL536531 0.71 CXCR3 (0.44) ESR1CYP2C9ESR2TEAD1
SCHEMBL2870866 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9812652-B2 Cyclic azine compound having adamantyl group, production method, and organic electroluminescent device containing it as constituent component TOSOH CORPORATION (JP) 2017-11-07 US disclosed
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT TOSOH CORPORATION (JP) 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160372678-A1 CYCLIC AZINE COMPOUND HAVING ADAMANTYL GROUP, PRODUCTION METHOD, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING IT AS CONSTITUENT COMPONENT CHRM1, AFF1, AZI2 ESR1 244/4885CYP2C9 706/4885ESR2 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.